NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
Nuvation Bio Inc. (NUVB) shares gained Monday after the company reported positive long-term data for its experimental brain cancer drug safusidenib, prompting RBC to highlight a potential market opportunity exceeding $3 billion.According to TheFly, RBC Capital analyst Leonid Timashev said the updat…